三月田 祐平

Medicine & Life Sciences

1. Glioblastoma 100%
2. Glioma 83%
3. Bevacizumab 52%
4. Mutation 38%
5. Oligodendroglioma 31%
6. Temozolomide 31%
7. Survival 22%
8. Neoplasms 22%
9. Epigenome 17%
10. Elderly 17%
11. Isocitrate Dehydrogenase 17%
12. Clinical Deterioration 15%
13. hydrogen sulfite 15%
14. Histones 15%
15. Cerebellopontine Angle 15%
16. Lab-On-A-Chip Devices 15%
17. Craniopharyngioma 14%
18. Brain Neoplasms 14%
19. Rivaroxaban 14%
20. Temporal Arteries 14%
21. Whole Genome Sequencing 14%
22. Central Nervous System Neoplasms 13%
23. Single-Stranded DNA 13%
24. Salvage Therapy 13%
25. Pediatrics 13%
26. Partial Epilepsy 13%
27. Neurilemmoma 13%
28. Status Epilepticus 12%
29. Freezing 12%
30. Japan 12%
31. Facial Nerve 12%
32. Meningioma 12%
33. Middle Cerebral Artery 12%
34. Thrombocytopenia 10%
35. Ligation 9%
36. Cerebrospinal Fluid 9%
37. Neuroepithelial Neoplasms 9%
38. N(4)-oleylcytosine arabinoside 9%
39. Perfusion 9%
40. Genetic Markers 9%
41. Hemorrhage 9%
42. Methylation 8%
43. Alzheimer Disease 8%
44. Endothelial Cells 8%
45. Craniotomy 8%
46. Loss of Heterozygosity 8%
47. Retrospective Studies 7%
48. Therapeutics 7%
49. Databases 7%